Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Review. Evidence-based treatments of addiction.

Literature DB >> 18640914

Review. Evidence-based treatments of addiction.

Abstract

Both pharmacotherapy and behavioural treatment are required to relieve the symptoms of addictive disorders. This paper reviews the evidence for the benefits of pharmacotherapy and discusses mechanisms where possible. Animal models of addiction have led to some medications that are effective in reducing symptoms and improving function but they do not produce a cure. Addiction is a chronic disease that tends to recur when treatment is stopped; thus, long-term treatment is recommended.

Entities: Disease

Mesh：

Substances：
Illicit Drugs

Year: 2008 PMID： 18640914 PMCID： PMC2607333 DOI： 10.1098/rstb.2008.0105

Source DB: PubMed Journal: Philos Trans R Soc Lond B Biol Sci ISSN： 0962-8436 Impact factor: 6.237

67 in total

1. The Marijuana Treatment Project: rationale, design and participant characteristics.

Authors: Robert S Stephens; Thomas F Babor; Ronald Kadden; Michael Miller
Journal: Addiction Date: 2002-12 Impact factor: 6.526

2. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study.

Authors: Charles A Dackis; Kevin G Lynch; Elmer Yu; Frederick F Samaha; Kyle M Kampman; James W Cornish; Amy Rowan; Sabrina Poole; Lenae White; Charles P O'Brien
Journal: Drug Alcohol Depend Date: 2003-05-01 Impact factor: 4.492

Review 3. Behavioral therapies for substance abuse.

Authors: A R Childress; A T McLellan; C P O'Brien
Journal: Int J Addict Date: 1985 Jun-Jul

4. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.

Authors: Joel Gelernter; Ralitza Gueorguieva; Henry R Kranzler; Huiping Zhang; Joyce Cramer; Robert Rosenheck; John H Krystal
Journal: Alcohol Clin Exp Res Date: 2007-04 Impact factor: 3.455

5. Clinical relevance of cannabis tolerance and dependence.

Authors: R T Jones; N L Benowitz; R I Herning
Journal: J Clin Pharmacol Date: 1981 Aug-Sep Impact factor: 3.126

6. Alteration of ethanol self-administration by naltrexone.

Authors: H L Altshuler; P E Phillips; D A Feinhandler
Journal: Life Sci Date: 1980-03-03 Impact factor: 5.037

7. A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms.

Authors: Kyle M Kampman; Charles Dackis; Kevin G Lynch; Helen Pettinati; Carlos Tirado; Peter Gariti; Thorne Sparkman; Michal Atzram; Charles P O'Brien
Journal: Drug Alcohol Depend Date: 2006-05-11 Impact factor: 4.492

8. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model.

Authors: K M Kantak; S L Collins; E G Lipman; J Bond; K Giovanoni; B S Fox
Journal: Psychopharmacology (Berl) Date: 2000-02 Impact factor: 4.530

9. Modafinil and cocaine interactions.

Authors: Robert Malcolm; Karla Swayngim; Jennifer L Donovan; C Lindsay DeVane; Ahmed Elkashef; Nora Chiang; Roberta Khan; Jurij Mojsiak; Donald L Myrick; Sarra Hedden; Kristi Cochran; Robert F Woolson
Journal: Am J Drug Alcohol Abuse Date: 2006 Impact factor: 3.829

10. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients.

Authors: David W Oslin; Wade Berrettini; Henry R Kranzler; Helen Pettinati; Joel Gelernter; Joseph R Volpicelli; Charles P O'Brien
Journal: Neuropsychopharmacology Date: 2003-06-18 Impact factor: 7.853

29 in total

1. Compound stimulus presentation and the norepinephrine reuptake inhibitor atomoxetine enhance long-term extinction of cocaine-seeking behavior.

Authors: Patricia H Janak; M Scott Bowers; Laura H Corbit
Journal: Neuropsychopharmacology Date: 2011-11-16 Impact factor: 7.853

2. Amygdala 14-3-3ζ as a novel modulator of escalating alcohol intake in mice.

Authors: Heidi M B Lesscher; Julia M Houthuijzen; Marian J Groot Koerkamp; Frank C P Holstege; Louk J M J Vanderschuren
Journal: PLoS One Date: 2012-05-22 Impact factor: 3.240

Review 3. Neuromodulation interventions for addictive disorders: challenges, promise, and roadmap for future research.

Authors: Primavera A Spagnolo; David Goldman
Journal: Brain Date: 2017-05-01 Impact factor: 13.501

4. Repeated transcranial direct current stimulation prevents abnormal behaviors associated with abstinence from chronic nicotine consumption.

Authors: Solène Pedron; Julie Monnin; Emmanuel Haffen; Daniel Sechter; Vincent Van Waes
Journal: Neuropsychopharmacology Date: 2013-10-24 Impact factor: 7.853

Review 5. The role of functional postsynaptic NMDA receptors in the central nucleus of the amygdala in opioid dependence.

Authors: Michael J Glass
Journal: Vitam Horm Date: 2010 Impact factor: 3.421

9. The association between negative affect and prescription opioid misuse in patients with chronic pain: the mediating role of opioid craving.

Authors: Marc O Martel; Andrew J Dolman; Robert R Edwards; Robert N Jamison; Ajay D Wasan
Journal: J Pain Date: 2013-10-12 Impact factor: 5.820

Review 10. Neuroimmune basis of alcoholic brain damage.

Authors: Fulton T Crews; Ryan P Vetreno
Journal: Int Rev Neurobiol Date: 2014 Impact factor: 3.230